Sign in
CompletedPhase 2

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
43 people enrolled
Started
11 Apr 2023
Ended
7 Jul 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cannabidiol
  • Placebo
Record updated
17 December 2025

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Ability to provide valid informed consent
  • 18-60 years old
  • Current or history of TBI as identified by the Ohio Identification Method
  • TBI severity is mild or moderate based on the VA/DoD Classification of TBI Severity
  • TBI event must have resulted in hospital evaluation (emergency department or other hospital-based assessment) or evaluation within a clinical setting, except in cases in which the TBI was acquired in a military deployment context in which medical services were not immediately available
  • Ongoing neuropsychiatric symptoms (i.e., depressive, anxiety, pain, cognitive complaints, or sleep complaints) that are plausibly associated with TBI and not better accounted for by co-occurring medical or psychological health conditions
  • Not currently in another treatment study for TBI-related symptoms or co-occurring medical or psychological health conditions
  • Co-occurring treatments must be stable in type, dose, and frequency for the four weeks preceding study enrollment and participants must commit to making no changes in these co-occurring treatments during the study

Who cannot take part

  • Reported use of other drugs (cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs of abuse at baseline
  • History of autism spectrum disorders, intellectual disability, and/or serious neurological or central nervous system disease that would be expected to affect cognition (e.g., epilepsy, tumors, multiple sclerosis)
  • Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022)
  • Meets criteria for major depressive episode as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022) and with a Beck Depression Inventory-2 score > 24
  • History of significant systemic illness or unstable medical condition
  • Alcohol use disorder score of 5 or greater, or substance use disorder, based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022), in the six months preceding study enrollment
  • Current diagnosis of a seizure disorder or epilepsy
  • Currently taking medications known to be contraindicated with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate)
  • Liver function enzymes (AST, ALT) that are greater than 2x normal
  • Currently incarcerated, paroled, or on probation
  • Participant has retained an attorney in relation to the TBI
  • Pregnant at the time of study enrollment or unwilling to commit to the use of two forms of contraception throughout the duration of the study
  • Vision, hearing, or communication impairments that preclude valid completion of study assessments
  • Evidence of poor effort (TOMMe < 8) on neuropsychological testing at baseline/Week 0
  • Current suicidal ideation, as indicated by Beck Depression Inventory-2 item #9 score > 0, or C-SSRS endorsement of item #2, or verbal or written report of current suicidal ideation by the participant to any study team member
  • Report using cannabis once daily or more than once daily over the last 12 months
  • Report current use of CBD for medical reasons or TBI symptoms

Where in United States

  • University of Colorado AnschutzAurora, United States

About the trial

What the trial wants to find out

This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

The 3 groups in the trial

  • Full Spectrum CannabidiolExisting treatment, for comparison

    Full Spectrum Cannabidiol (\<0.3% THC) Oral softgel capsule, 210mg/day

    Treatment: Cannabidiol

  • Broad Spectrum CannabidiolExisting treatment, for comparison

    Broad Spectrum Cannabidiol (0.0% THC) Oral softgel capsule, 210mg/day

    Treatment: Cannabidiol

  • Hemp Seed OilPlacebo, for comparison

    Placebo Oral softgel capsule, 210mg/day

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 December 2025